DUBLIN, Calif., Jan. 2 (UPI) -- The U.S. Army announced it has selected California-based Microchip Biotechnologies Inc. to participate in the inaugural commercialization pilot program.
MBI has been selected as one of 25 firms out of 416 applicants for the Army's new commercialization pilot program that identifies small business innovation research firms that have phase II projects with a potential to transfer technologies into commercial products under Army requirements.
MBI is currently developing an Army-funded biothreat detection system, the Apollo next-generation fluidics platform, that company officials say integrates "advanced microfluidic sample preparation and analytical capabilities for DNA sequencing, biodefense and forensics applications among others," the release said.
"The acceptance of MBI by the Army to participate in the commercialization pilot program is a further validation of our commitment to develop and commercialize microfluidic technologies for the protection of the combat troops and civilian populations," Stevan Jovanovich, MBI president and chief executive officer, said in a statement.
